1.	A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CINC280X2202, 2011-002569-39, NCT01610336
2.	Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CINC280X2201, NCT01737827
3.	LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLGX818X2102, 2012-004798-17, NCT01820364
4.	Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CINC280X2102, 2010-024101-12, NCT01324479
5.	A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CINC280X1101, NCT01546428